Polpharma Biologics specializes in the development and manufacturing of biopharmaceuticals, focusing on both biosimilars and innovative molecules. The company operates in the biopharmaceutical market, providing contract development and manufacturing organization (CDMO) services. Polpharma Biologics serves a diverse range of clients, including pharmaceutical companies and biotech firms, who are developing therapeutics to improve patient health and address unmet medical needs. The business model revolves around offering end-to-end solutions, from cell line development and process development to clinical manufacturing and commercial scale production. Revenue is generated through service contracts with clients who require specialized expertise and state-of-the-art facilities for their biopharmaceutical projects.

Polpharma Biologics operates multiple international centers of excellence across Europe, equipped with cutting-edge tools and methods. The company is committed to executing commercial launches on time and ensuring cost-effective supply. Their services include drug product development, cGMP manufacturing of sterile biologicals in both liquid and lyophilized forms, and microbial processes and manufacturing. The company also boasts a state-of-the-art biopharmaceutical cGMP fill-finish plant in Europe.

Keywords: biopharmaceuticals, CDMO, biosimilars, innovative molecules, cell line development, process development, clinical manufacturing, commercial production, cGMP, Europe.